Abstract: A non-oriented electrical steel sheet according to an embodiment of the present invention may include, by weight, by weight, 2.0 to 3.5% of Si, 0.3 to 2.5% of Al, 0.3 to 2.5% of Mn, individually or in a total amount of 0.0005 to 0.03% of at least one of Ga and Ge, and the remainder including Fe and impurities, and may satisfy the following Formula 1. 0.2?([Si]+[Al]+0.5×[Mn])/(([Ga]+[Ge])×1000)?5.27??[Formula 1] ([Si], [Al], [Mn], [Ga] and [Ge] represent the content (% by weight) of Si, Al, Mn, Ga and Ge, respectively).

Abstract: Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Abstract: Provided is a method of setting an ultrasound preset, which includes displaying a selection window on a screen for selecting the preset corresponding to the selected probe upon at an event of selecting the probe, and to hide the selection window, in the case a user input for selecting the preset corresponding to the selected probe is not entered within a reference time.

Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.

Abstract: The present invention relates to an antibacterial dressing and a method for preparing the same. According to the present invention, there are provided an antibacterial dressing containing a rapid cell membrane-penetrating component that exhibits excellent bactericidal and antibacterial activities by disrupting the structure and synthesis of protein and nucleic acid, and a method for preparing the same.

Abstract: Disclosed are oxadiazole compounds and pharmaceutically acceptable salts thereof. The compounds and pharmaceutically acceptable salts thereof are specifically suitable for the treatment of neurological diseases such as epilepsy.

Abstract: A non-oriented electrical steel sheet according to an exemplary embodiment of the present invention includes at least one of 2.0 to 3.5% of Si, 0.3 to 3.5% of Al, 0.2 to 4.5% of Mn, 0.0030 to 0.2% of Sn, 0.0030 to 0.15% of Sb, 0.0040 to 0.18% of P, 0.0005 to 0.02% of Zn, and 0.0005 to 0.01% of Y for wt %, a remainder of Fe, and inevitable impurities, and satisfying Formula 1: 0.05?([Sn]+[Sb])/[P]?25??[Formula 1] (here, [Sn], [Sb], and [P] represent contents (wt %) of Sn, Sb, and P.

Abstract: A non-oriented electrical steel sheet according to an exemplary embodiment of the present invention includes 2.0 to 4.0% of Si, 0.05 to 1.5% of Al, 0.05 to 2.5% of Mn, equal to or less than 0.005% of C (excluding 0%), equal to or less than 0.005% of N (excluding 0%), 0.001 to 0.1% of Sn, 0.001 to 0.1% of Sb, 0.001 to 0.1% of P, 0.001 to 0.01% of As, 0.0005 to 0.01% of Se, 0.0005 to 0.01% of Pb, 0.0005 to 0.01% of Bi, a remainder of Fe, and inevitable impurities, as wt %, wherein a Taylor factor (M) of each crystal grain included in a steel sheet is expressed in Formula 1, and an average Taylor factor value of the steel sheet is equal to or less than 2.75: M = ? ? CRSS [ Formula ? ? 1 ] (here, ? is a macro stress, and ?CRSS is a critical resolved shear stress.

Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.

Abstract: Antibodies that bind specifically to glycosylated PD-L1 relative to unglycosylated PD-L1 are provided. Antibodies that recognize specific epitopes of glycosylated PD-L1 protein and can block the binding of PD-L1 to PD-1 are provided. In some aspects, PD-L1 polypeptides comprising glycosylated amino acid residues at amino and carboxy terminal positions of the PD-L1 extracellular domain are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.

Abstract: A non-oriented electrical steel sheet according to an exemplary embodiment of the present invention includes, by weight %, Si: 2.5 to 6.0%, Al: 0.2 to 3.5%, Mn: 0.2 to 4.5%, Cr: 0.01 to 0.2%, P: 0.005 to 0.08%, Mg: 0.0005 to 0.05%, and a remainder including Fe and inevitable impurities, while satisfying Equation 1 below, and formed with an inner oxidation layer of a 0.2 to 5 ?m thickness inside a base steel sheet. ?2.5?[P]/[Cr]?[Mg]×100?6.5??[Equation 1] (In Equation 1, [P], [Cr], and [Mg] respectively represent a content (by wt %) of P, Cr, and Mg.

Abstract: Disclosed are a display apparatus, where a component disposition area facing a component disposed on a lower end of a non-display area of a panel is removed in a lower substrate configuring the panel, and a method of manufacturing the same.

Abstract: Provided is a progress rate roll-up system for calculating a Level 3 progress rate based on a Level 4 progress rate. The progress rate roll-up system includes a Level association unit, a mapping association unit, and a Level 3 association unit. The progress rate roll-up system further includes at least one of a BEME database (DB), an EWS DB, an EIPS DB, a mapping DB, a EIPS_No_Group_MH DB, a CPVAL DB, and a EIPS_No_MH DB. Accordingly, because not only the Level 4 progress rate but also the Level 3 progress rate may be calculated, more accurate analysis data may be provided to complete a project within an allocated budget and a given construction period.

Abstract: Provided herein are molecules having an antigen binding fragment that immuno specifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immuno specifically binds to BTN1A1 dimers, such as anti-BTN1A1 dimer antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.

Abstract: Provided herein are methods for treating cancer using molecules having an antigen binding fragment that immunospecifically binds to BTN1A1 or a BTN1A1 ligand, such as anti-BTN1A1 antibodies or anti-BTN1A1 ligand antibodies. Also provided herein are BTN1A1 ligands, such as Galectin-1, Galectin-9, Neuropilin-2, and B- and T-Lymphocyte Attenuator.

Abstract: The present invention relates to an antibacterial dressing and a method for preparing the same. According to the present invention, there are provided an antibacterial dressing containing a rapid cell membrane-penetrating component that exhibits excellent bactericidal and antibacterial activities by disrupting the structure and synthesis of protein and nucleic acid, and a method for preparing the same.

Abstract: A non-oriented electrical steel sheet according to an embodiment of the present invention, comprises: Si: 2.0 to 3.5%, Al: 0.05 to 2.0%, Mn: 0.05 to 2.0%, In: 0.0002 to 0.003% by wt % and Fe and inevitable impurities as the remainder.

Abstract: An Al—Fe alloy coated steel sheet includes a base steel sheet and an alloy coating layer, wherein the base steel sheet includes, by wt %, C: 0.1%˜0.5%, Si: 0.01%˜2%, Mn: 0.01%˜10%, P: 0.001%˜0.05%, S: 0.0001%˜0.02%, Al: 0.001%˜1.0%, N: 0.001%˜0.02%, and the balance of Fe and other impurities, wherein the alloy coating layer includes: an Al—Fe alloy layer I formed on the base steel sheet and having a Vickers hardness of 200˜800 Hv; an Al—Fe alloy layer III formed on the Al—Fe alloy layer I and having a Vickers hardness of 700˜1200 Hv; and an Al—Fe alloy layer II formed in the Al—Fe alloy layer III continuously or discontinuously in a length direction of the steel sheet, and having a Vickers hardness of 400˜900 Hv, wherein an average oxygen content at a depth of 0.1 ?m from a surface of the oxide layer is 20% or less by weight.

Abstract: A non-oriented electrical steel sheet according to an embodiment of the present invention may include, by weight, by weight, 2.0 to 3.5% of Si, 0.3 to 2.5% of Al, 0.3 to 2.5% of Mn, individually or in a total amount of 0.0005 to 0.03% of at least one of Ga and Ge, and the remainder including Fe and impurities, and may satisfy the following Formula 1. 0.2?([Si]+[Al]+0.5×[Mn])/(([Ga]+[Ge])×1000)?5.27 ??[Formula 1] ([Si], [Al], [Mn], [Ga] and [Ge] represent the content (% by weight) of Si, Al, Mn, Ga and Ge, respectively.

Abstract: The present invention proposes a valve assembly in which the flow direction of a fluid is controlled according to a tilt angle and a large amount of fluid can be moved.